drugset / Trial / NCT00863850

Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy

NCT00863850

Phase 1 Completed 6 enrolled Cephalon
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy (Hematologic or Nonhematologic)

Timeline

Start
2009-05
Primary completion
2010-02
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule 120 mg/m2 Intravenous

Indications